Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 11/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470323 | 0.89 | MAPT (0.52) | NPC1RAB9ASMN1; SMN2KDM4EPOLB | |
| SCHEMBL15475660 | 0.89 | NPC1 (0.52) | NPC1RAB9AHCRTR1CASP3SENP8 | |
| SCHEMBL15475631 | 0.89 | NPC1 (0.52) | NPC1RAB9AHCRTR1CASP3SENP8 | |
| SCHEMBL457202 | 0.88 | DPP4 (0.52) | SMN1; SMN2KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL16271158 | 0.84 | NPC1 (0.47) | NPC1RAB9AHCRTR1CASP3SENP8 | |
| SCHEMBL15226771 | 0.82 | MAPT (0.48) | SMN1; SMN2KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL470433 | 0.81 | KDM4E (0.41) | SMN1; SMN2KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL459528 | 0.80 | MAPT (0.46) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL15475806 | 0.80 | MAPT (0.56) | NPC1RAB9AHCRTR1CASP3SENP8 | |
| SCHEMBL8570609 | 0.80 | MAPT (0.62) | NPC1RAB9ASMN1; SMN2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10125148-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-11-13 | — | — | US | disclosed |
| US-9932356-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-9932356-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-9932356-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-9834566-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834566-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834566-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| EP-3152211-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2017-04-12 | — | — | EP | disclosed |
| EP-3152215-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2017-04-12 | — | — | EP | disclosed |
| US-20170057977-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-03-02 | — | — | US | disclosed |
| WO-2015123182-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-20 | — | — | WO | disclosed |
| EP-2888266-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2015-07-01 | — | — | EP | disclosed |
| US-8906929-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906929-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906929-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
| WO-2014028384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-20 | — | — | WO | disclosed |
| WO-2014028384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10125148-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | TYMP, EIF2AK2, MAVS | NPC1 632/4885RAB9A 2398/4885HCRTR1 4631/4885 |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | NPC1 434/4885RAB9A 1173/4885HCRTR1 4195/4885 |
| US-20170057977-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | TYMP, TK1, TYMS | NPC1 1106/4885RAB9A 3110/4885HCRTR1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.